765 NITRIC OXIDE-DONATING STATINS EXERT BENEFICIAL EFFECTS ON ACUTE VASCULAR INFLAMMATION IN NORMOCHOLESTEROLEMIC RABBITS
Atherosclerosis Supplements, Volume 12, Issue 1, June 2011, Page 160
R. Baetta, A. Granata, L. Arnaboldi, N. Ferri, S. Bellosta, A. Bonomo, D. Miglietta, P. Pfister, A. Corsini
79th EAS Congress Atherosclerosis Supplements 12, no. 1 (2011) 13–184 169
802 SAFETY AND EFFICACY OF NCX 6560, A NITRIC OXIDE (NO)-
DONATING ATORVASTATIN, IN A FIRST-INTO-MAN RANDOMISED,
DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED STUDY
P. Pfister1, J. Djian1, T. Ferreira1, R. Maucci2, J. Croizier1, P. Tocchetti2,
L. Gheyle3, S. Mesens3. 1NicOx SA, Sophia-Antipolis, France, 2NicOx
Research Institute, Bresso, Italy, 3SGS Life Science Services, Antwerpen,
Belgium
NCX 6560, a novel compound releasing both NO and atorvastatin (ATV), was
as effective as equimolar atorvastatin on lipid lowering but more effective on
anti-thrombotic, anti-inflammatory properties and endothelial function in animal
models. The aim of this FIM study was to assess the safety, tolerability, and
pharmacokinetics of NCX 6560 and its pharmacodynamic effects on lipids.
Multiple ascending oral doses of NCX 6560 (24, 48, 96 and 144 mg od), ATV
40 mg od and placebo were administered for 2 weeks to 48 male healthy
subjects with high LDL-C (between 130–180 mg/dL). Subjects were randomized
as follows: 8 on active, 2 on control and 2 on placebo in each cohort. Doses
were escalated after evaluation of safety, tolerability and pharmacokinetics.
Treatment with NCX 6560 was safe and well tolerated and no SAEs or severe
AEs were reported.
No significant increase in liver enzymes or CK was observed
even at the highest dose. A dose-related decrease from baseline in LDL-C (up
to 57%), total cholesterol (up to 45%), and Apo B levels (up to 49%) was
observed, with 48 mg NCX 6560 and 40 mg ATV showing equiefficacy. The
pharmacokinetic profile of ATV following NCX 6560 administration was dose
proportional up to 96 mg. After 48 mg NCX 6560, the bioavailability of ATV and
its active metabolites was around 50% of the bioavailability following 40 mg
ATV.
NCX 6560 had the same lipid-lowering effect of equimolar ATV despite a lower
exposure to ATV and its active metabolites.
et on se rappelle de l'article recent paru en septembre
A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy Original Research Article
Pharmacological Research, Volume 64, Issue 3, September 2011, Pages 210-217
Clara Sciorati, Daniela Miglietta, Roberta Buono, Viviana Pisa, Dario Cattaneo, Emanuele Azzoni, Silvia Brunelli, Emilio Clementi